Karyopharm Therapeutics
(NASDAQ:KPTI)
$1.15
0[0.00%]
At close: May 20
$1.15
0[0.00%]
After Hours: 4:55PM EDT
Consensus Rating1
Overweight
Highest Price Target1
$27.00
Lowest Price Target1
$3.00
Consensus Price Target1
$8.73

Karyopharm Therapeutics Stock (NASDAQ:KPTI), Analyst Ratings, Price Targets, Predictions

Karyopharm Therapeutics Inc has a consensus price target of $8.73, established from looking at the 40 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and Piper Sandler on May 9, 2024, March 1, 2024, and November 3, 2023. With an average price target of $7 between HC Wainwright & Co., HC Wainwright & Co., and Piper Sandler, there's an implied 508.70% upside for Karyopharm Therapeutics Inc from these 3 analyst ratings.

Analyst Trend
1
Mar
1
May
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.4
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

HC Wainwright & Co.
Piper Sandler
RBC Capital
Morgan Stanley
Wedbush

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Karyopharm Therapeutics

Buy NowGet Alert
05/09/2024Buy Now595.65%HC Wainwright & Co.
Edward White
→ $8ReiteratesBuy → BuyGet Alert
03/01/2024Buy Now595.65%HC Wainwright & Co.
Edward White
$10 → $8MaintainsBuyGet Alert
11/03/2023Buy Now334.78%Piper Sandler
Christopher Raymond
$7 → $5MaintainsOverweightGet Alert
11/03/2023Buy Now160.87%RBC Capital
Brian Abrahams
$4 → $3MaintainsOutperformGet Alert
08/07/2023Buy Now247.83%Morgan Stanley
Michael Ulz
$5 → $4MaintainsEqual-WeightGet Alert
08/03/2023Buy Now508.7%Piper Sandler
Christopher Raymond
$8 → $7MaintainsOverweightGet Alert
08/03/2023Buy Now247.83%RBC Capital
Brian Abrahams
$5 → $4MaintainsOutperformGet Alert
08/03/2023Buy Now769.57%HC Wainwright & Co.
Edward White
→ $10ReiteratesBuy → BuyGet Alert
07/26/2023Buy Now247.83%Wedbush
David Nierengarten
$7 → $4MaintainsNeutralGet Alert
07/26/2023Buy Now769.57%HC Wainwright & Co.
Edward White
→ $10ReiteratesBuy → BuyGet Alert
07/18/2023Buy Now769.57%HC Wainwright & Co.
Edward White
→ $10ReiteratesBuy → BuyGet Alert
05/05/2023Buy Now334.78%RBC Capital
Brian Abrahams
$6 → $6MaintainsOutperformGet Alert
05/05/2023Buy Now769.57%HC Wainwright & Co.
Edward White
$16 → $10MaintainsBuyGet Alert
05/05/2023Buy Now769.57%Baird
Mitch Collett
$14 → $10MaintainsOutperformGet Alert
04/19/2023Buy Now1291.3%HC Wainwright & Co.
Edward White
→ $16Reiterates → BuyGet Alert
02/22/2023Buy Now1291.3%HC Wainwright & Co.
Edward White
→ $16MaintainsBuyGet Alert
02/16/2023Buy Now1291.3%HC Wainwright & Co.
Edward White
→ $16Reiterates → BuyGet Alert
01/27/2023Buy Now334.78%Morgan Stanley
Michael Ulz
$7 → $5MaintainsEqual-WeightGet Alert
01/19/2023Buy Now595.65%Piper Sandler
Christopher Raymond
→ $8Initiates → OverweightGet Alert
01/10/2023Buy Now1291.3%HC Wainwright & Co.
Edward White
$18 → $16MaintainsBuyGet Alert
01/10/2023Buy Now334.78%SVB Leerink
Jonathan Chang
$6 → $5MaintainsMarket PerformGet Alert
11/04/2022Buy Now769.57%RBC Capital
Brian Abrahams
$7 → $10UpgradeSector Perform → OutperformGet Alert
11/04/2022Buy Now421.74%SVB Leerink
Jonathan Chang
$5 → $6MaintainsMarket PerformGet Alert
09/09/2022Buy Now508.7%Morgan Stanley
Michael Ulz
$10 → $7MaintainsEqual-WeightGet Alert
08/05/2022Buy Now1465.22%HC Wainwright & Co.
Edward White
$21 → $18MaintainsBuyGet Alert
08/05/2022Buy Now1117.39%Baird
Colleen Kusy
$17 → $14MaintainsOutperformGet Alert
08/05/2022Buy Now595.65%Barclays
Peter Lawson
$14 → $8MaintainsOverweightGet Alert
05/05/2022Buy Now334.78%SVB Leerink
Jonathan Chang
$6 → $5MaintainsMarket PerformGet Alert
03/18/2022Buy Now1813.04%HC Wainwright & Co.
Edward White
$23 → $22MaintainsBuyGet Alert
03/08/2022Buy Now595.65%RBC Capital
Brian Abrahams
$12 → $8MaintainsSector PerformGet Alert

FAQ

Q

What is the target price for Karyopharm Therapeutics (KPTI)?

A

The latest price target for Karyopharm Therapeutics (NASDAQ: KPTI) was reported by HC Wainwright & Co. on May 9, 2024. The analyst firm set a price target for $8.00 expecting KPTI to rise to within 12 months (a possible 595.65% upside). 11 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Karyopharm Therapeutics (KPTI)?

A

The latest analyst rating for Karyopharm Therapeutics (NASDAQ: KPTI) was provided by HC Wainwright & Co., and Karyopharm Therapeutics reiterated their buy rating.

Q

When was the last upgrade for Karyopharm Therapeutics (KPTI)?

A

The last upgrade for Karyopharm Therapeutics Inc happened on November 4, 2022 when RBC Capital raised their price target to $10. RBC Capital previously had a sector perform for Karyopharm Therapeutics Inc.

Q

When was the last downgrade for Karyopharm Therapeutics (KPTI)?

A

The last downgrade for Karyopharm Therapeutics Inc happened on November 19, 2021 when Morgan Stanley changed their price target from $27 to $10 for Karyopharm Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Karyopharm Therapeutics (KPTI)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Karyopharm Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Karyopharm Therapeutics was filed on May 9, 2024 so you should expect the next rating to be made available sometime around May 9, 2025.

Q

Is the Analyst Rating Karyopharm Therapeutics (KPTI) correct?

A

While ratings are subjective and will change, the latest Karyopharm Therapeutics (KPTI) rating was a reiterated with a price target of $0.00 to $8.00. The current price Karyopharm Therapeutics (KPTI) is trading at is $1.15, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch